Home / Publication / A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population

刊物

齐洛韦坦单抗维多汀（Zilovertamab Vedotin）在血液恶性肿瘤患者中的序贯群体药代动力学模型推断至儿童群体

Author(s): Thijs J. Zweers, Jos Lommerse, Eline van Maanen, Manash S. Chatterjee

Year: 2024 年 10 月 22 日

Certara Announces Second Annual Certainty U.S. Event

公告

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions

网络研讨会

In case you missed it: CHI + Certara Webinar on Artificial Intelligence (AI) -Powered Model-Informed Drug Development (MIDD)

博客

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

新闻发布

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

齐洛韦坦单抗维多汀（Zilovertamab Vedotin）在血液恶性肿瘤患者中的序贯群体药代动力学模型推断至儿童群体

齐洛韦坦单抗维多汀（Zilovertamab Vedotin）在血液恶性肿瘤患者中的序贯群体药代动力学模型推断至儿童群体

Certara Announces Second Annual Certainty U.S. Event

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions

In case you missed it: CHI + Certara Webinar on Artificial Intelligence (AI) -Powered Model-Informed Drug Development (MIDD)

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

订阅时事通讯

快捷链接

解决方案

联系我们